AGN has been the topic of several other research reports. Credit Suisse Group AG began coverage on Allergan PLC in a research report on Monday, July 25th. They issued an outperform rating and a $327.00 price target on the stock. Zacks Investment Research cut Allergan PLC from a buy rating to a hold rating in a research report on Tuesday, July 26th. Vetr cut Allergan PLC from a strong-buy rating to a buy rating and set a $283.05 price target on the stock. in a research report on Monday, August 8th. Leerink Swann set a $294.00 target price on Allergan PLC and gave the stock a buy rating in a research report on Monday, August 8th. Finally, Goldman Sachs Group Inc. reiterated a buy rating and set a $300.00 target price on shares of Allergan PLC in a research report on Tuesday, September 27th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Allergan PLC currently has an average rating of Buy and a consensus price target of $302.52.
Shares of Allergan PLC (NYSE:AGN) opened at 238.92 on Tuesday. The firm has a market cap of $94.60 billion, a PE ratio of 22.75 and a beta of 0.81. The company has a 50 day moving average price of $239.97 and a 200 day moving average price of $239.33. Allergan PLC has a 12-month low of $195.50 and a 12-month high of $322.68.
Allergan PLC (NYSE:AGN) last issued its quarterly earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.34 by $0.01. The firm had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.41 EPS. On average, analysts forecast that Allergan PLC will post $14.00 earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in the company. AMP Capital Investors Ltd increased its stake in shares of Allergan PLC by 4.9% in the first quarter. AMP Capital Investors Ltd now owns 163,096 shares of the company’s stock valued at $44,844,000 after buying an additional 7,588 shares in the last quarter. Arizona State Retirement System increased its stake in shares of Allergan PLC by 0.9% in the first quarter. Arizona State Retirement System now owns 108,577 shares of the company’s stock valued at $29,102,000 after buying an additional 1,000 shares in the last quarter. Montag & Caldwell LLC increased its stake in shares of Allergan PLC by 16.2% in the second quarter. Montag & Caldwell LLC now owns 687,035 shares of the company’s stock valued at $158,767,000 after buying an additional 95,951 shares in the last quarter. Intermede Investment Partners Ltd bought a new stake in shares of Allergan PLC during the second quarter valued at about $37,790,000. Finally, Retirement Systems of Alabama increased its stake in shares of Allergan PLC by 15.0% in the second quarter. Retirement Systems of Alabama now owns 336,058 shares of the company’s stock valued at $77,660,000 after buying an additional 43,898 shares in the last quarter. Institutional investors and hedge funds own 85.19% of the company’s stock.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.